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Abstract
Background: Continuous progression of lesions despite an adequate treatment has been described in
tubercular multifocal serpiginoid choroiditis. Reported treatments for this paradoxical response include
systemic steroids, immunosuppressive drugs, and intravitreal methotrexate. We describe the use of
dexamethasone intravitreal implants in a patient presenting with this condition.
Findings: A 46-year-old woman sought medical attention for scotomas in her left eye. Tests suggested
multifocal serpiginoid choroiditis associated with latent tuberculosis infection, and hence, she was started on
anti-tuberculosis drugs in combination with corticosteroids. Given that lesions progressed despite this
treatment, we began treatment with dexamethasone intravitreal implants. After injection of the second
implant, we succeeded in inactivating the inflammatory process.
Conclusions: Dexamethasone intravitreal implants may be a suitable alternative to systemic steroids or
immunosuppressive therapy in the management of continuous progression of lesions in tubercular multifocal
serpiginoid choroiditis.
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Findings
Introduction
Multifocal serpiginoid choroiditis (MSC) is a rare
entity producing chronic recurrent progressive inflam-
mation of the retinal pigment epithelium and chorio-
capillaris that is associated with latent tuberculosis
infection [1]. Treatment consists of anti-tuberculosis
antibiotics and corticosteroids. A paradoxical response
to treatment has been described in some patients
with MSC, consisting of progression of the disease
despite appropriate treatment. We describe the case
of a patient with this condition who was treated with
dexamethasone intravitreal implants to manage this
paradoxical response.
Case report
A 46-year-old women with myopia (7 dioptres) in
both eyes sought medical attention for a 1-month
history of paracentral scotomas in her left eye. Her
personal history included contact with a patient with
tuberculosis 20 years earlier and a tick bite 10 years
earlier with no clinical manifestations. Eye examin-
ation found a best-corrected visual acuity of 1.0 in
both eyes, anterior segment slit lamp biomicroscopy
was normal in both eyes, and the intraocular pressure
was 19 mmHg in both eyes. Funduscopic examination
was normal in the right eye but revealed multifocal
serpiginoid lesions in the posterior pole and mid-
peripheral retina of the left eye, with some cells in
the vitreous body (Fig. 1).
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Requests were made for the following: serologies for
syphilis, Borrelia burgdorferi, hepatitis B and C, and
HIV, for which results were normal; quantiFERON
(Cellestis, Victoria, Australia) and Mantoux tests, which
were positive; and a chest X-ray, which produced no
abnormal findings.
We established the diagnosis of MSC and initiated
treatment with anti-tuberculosis drugs: ethambutol,
isoniazid, pyrazinamide, and rifampicin for 2 months,
together with a tapered dose of oral prednisone (with
a starting dose of 30 mg). Initially, lesions stabilised
but when we decreased the dose of corticosteroids to
10 mg (in the third week of treatment), new lesions
started to appear (Fig. 2). We attempted to control
the inflammation with three intravenous pulses of
methylprednisolone (250 mg) and initiated a second
tapered course of corticosteroids, but once again, after
initial stabilisation, the lesions recurred (Fig. 3). At
that point, 2 months after having initiated the anti-
biotic treatment, we decided to treat the patient using
a dexamethasone intravitreal implant (OZURDEX;
Allergan, Inc., Irvine, CA). This stopped the progres-
sion of the lesions, and the antibiotic treatment with
rifampicin and isoniazid was continued (completing
9 months of treatment). The intraocular pressure was
19 mmHg in all subsequent checkups. Five months
later, we observed new lesions, and hence, a second
implant was used (Fig. 4). After this second injection,
lesions became inactive and no new inflammatory foci
have been observed, the intraocular pressure remaining at
19 mmHg at the most recent follow-up, 12 months after
this second treatment (Fig. 5). Visual acuity at this point
was 1.0 in both eyes.
Discussion
MSC is a type of posterior uveitis characterised by
recurrent and chronic inflammation of the retinal
pigment epithelium and choriocapillaris, associated
with latent tuberculosis infection [1]. The usual treat-
ment consists of administering anti-tuberculosis anti-
biotics together with oral corticosteroids. It has been
reported, however, that lesions progress in some
patients, despite appropriate treatment for tubercu-
losis. This paradoxical response has been attributed to
an elevated immune response to the release of tuber-
cular antigens; antibiotics may trigger the release of
these antigens as the mycobacteria are lysed [2]. A
remarkable point is that rifampicin, a commonly used
anti-tuberculosis drug, decreases bioavailability of
corticosteroids; hence, this may contribute to the
progression of inflammation. In fact, the dose of
Fig. 1 Retinography (a) and fundus autofluorescence imaging (b) on admission showing multifocal chorioretinitis lesions
Fig. 2 Retinography (a) and fundus autofluorescence imaging (b) showing the progression of lesions. The patient had initiated anti-tuberculosis
treatment and tapered doses of oral prednisone. When she decreased the dose to 10 mg, new lesions started to appear
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corticosteroids needs to be doubled when patients are
treated with rifampicin [3].
Gupta et al. [4] described the progression of the
disease in 12 out of 84 patients (14 %) with MSC. The
continued progression was managed by increasing the
dosage of oral prednisolone in nine patients (two of
them receiving also intravenous metilprednisolone)
while in four patients, immunosuppressive agents
(cyclophosphamide or azathioprine) were given to
control the condition. In the other three patients, the
dosage of oral corticosteroid was not increased
further. Basu et al. [5] described the progression of
the disease in 26 out of 106 patients (24.5 %) with
different types of presumed tuberculous uveitis; 24
patients had MSC, and of these, seven showed
progression of the disease; all of these patients were
effectively managed by increasing the dose of cortico-
steroids and continued antibiotics. Julian et al. [6]
described the use of intravitreal methotrexate in pa-
tients with MSC with active disease despite treatment
with systemic antibiotics. In their series of three eyes
from two patients, choroidal lesions healed within the
first month after the injection. Since dexamethasone
intravitreal implants have been shown to be very
effective in managing intraocular inflammation both
in non-infectious [7] and infectious uveitis [8], and a
local approach has the advantage of reducing the risk
of activating tubercular systemic disease, we consid-
ered this treatment a suitable option for our patient.
The treatment was effective, though two injections
were required. For 5 months after the first injection, we
observed healing of the lesions and no new ones ap-
peared. After this period, when the effect of the implant
would be expected to have worn off, recurrence was ob-
served, and this was effectively managed with a second
dexamethasone intravitreal implant. Though a paradox-
ical response is more frequent early after initiating anti-
biotic treatment, cases developing after as long as
5 months have been described [3]. The second flare-up
we observed falls into this category of late recurrences.
We believe that in such cases of MSC with a
paradoxical recurrence of inflammation, use of a
dexamethasone intravitreal implant, to our knowledge,
not previously described for this condition, may be a
suitable alternative to systemic immunosuppressive
therapy. Local management of the condition would
avoid inducing severe immunosuppression in patients
with a latent tuberculosis infection and hence, the
associated risk of developing active tuberculosis. On
the other hand, serpiginoid inflammatory lesions in
Fig. 3 Retinography (a) and fundus autofluorescence imaging (b) showing new lesions. The patient had initiated a second tapered course of
prednisone. At this point, a dexamethasone intravitreal implant was indicated
Fig. 4 Retinography (a) and fundus autofluorescence imaging (b) showing the progression of lesions 5 months after the injection of dexamethasone
intravitreal implant. A second injection was given
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the posterior segment of the eye (serpiginous-like
choroiditis) may be caused by infectious aetiologies
other than tuberculosis so they should be ruled out
before giving a dexamethasone intravitreal implant to
treat this condition [9].
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Fig. 5 Retinography (a) and fundus autofluorescence imaging (b) at the last follow-up visit (12 months after the second dexamethasone intravitreal
implant) showing healed lesions
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